Ulm

• A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan … Ended recruitment
  2023-503666-23-00 5 2024-06-07 Neovascular age-related macular degeneration
• A trial to learn if rilvegostomig with chemotherapy given after surgery is safe in people with biliary tract cancer and works to delay when … Ended recruitment
  2023-506054-20-00 5 2024-06-05 Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic chol
• A study to evaluate the efficacy and safety of JCAR017 in adult subjects with a type of cancer that affects B-cells, a type of white blood c … Ended recruitment
  2024-510966-18-00 4 2024-06-03 Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)
• Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended recruitment
  2022-500571-32-00 4 2024-05-15 Early-Stage Unfavorable Classical Hodgkin Lymphoma
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit … Ended recruitment
  2023-505928-59-00 5 2024-04-15 Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
• An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell pr … Ended recruitment
  2024-517959-12-00 9 2024-04-11 Relapsed/refractory B cell precursor acute lymphoblastic leukemia
• Study of HRO761 alone or in combination in cancer patients with specific DNA alterations called Microsatellite Instability-High or Mismatch … Ended recruitment
  2022-502314-93-00 1 2024-02-05 MSIhi or dMMR advanced unresectable or metastatic solid tumors
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• ViaskinTM Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy (VITESSE) Ended recruitment
  2022-502110-85-00 5 2024-01-18 Peanut allergy
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• A Phase III multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients Ended recruitment
  2023-505160-12-00 5 2023-12-04 Essential Thrombocythaemia
• A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended recruitment
  2022-502789-26-01 4 2023-11-03 Fibrostenotic Crohn’s Disease
• A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntingt … Ended recruitment
  2023-504628-24-00 4 2023-10-31 Huntington's Disease
• A single arm, open label extension (OLE), multicenter study to evaluate long-term safety and tolerability of pelacarsen (TQJ230) in patients … Ended recruitment
  2023-503611-16-00 5 2023-09-29 Apheresis
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe … Ended recruitment
  2022-501644-15-01 4 2023-09-28 Mild Cognitive Impairment due to Alzheimer's Disease Alzheimer's Disea
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T … Ended recruitment
  2022-501346-30-00 5 2023-09-25 Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
• A Study to Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospha … Ended recruitment
  2023-504028-24-00 5 2023-09-22 Large B-Cell Lymphoma
• Perioperative/Adjuvant atezolizumab in patients with MSI-high or MMRdeficient stage II high risk or stage III colorectal cancer ineligible f … Ended recruitment
  2024-515224-37-00 4 2023-08-29 Patients with MSI-high or MMR-deficient stage III colorectal cancer wh
• A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-20 … Ended recruitment
  2022-500758-41-00 1 2023-08-15 Amyotrophic lateral sclerosis
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• STEP Young: A research study on how well semaglutide helps children and teenagers with excess body weight lose weight Ended recruitment
  2022-502922-41-00 5 2023-07-03 Obesity and overweight
• A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended recruitment
  2024-515027-11-00 4 2023-06-29 Crohn’s disease

Showing 337–360 of 569 trials